One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses

Natalie S. Haddad,Doan C. Nguyen,Merin E. Kuruvilla,Andrea Morrison-Porter,Fabliha Anam,Kevin S. Cashman,Richard P. Ramonell,Shuya Kyu,Ankur Singh Saini,Monica Cabrera-Mora,Andrew Derrico,David Alter,John D. Roback,Michael Horwath,James B. O’Keefe,Henry M. Wu,An-Kwok Ian Wong,Alexandra W. Dretler,Ria Gripaldo,Andrea N. Lane,Hao Wu,Helen Y. Chu,Saeyun Lee,Mindy Hernandez,Vanessa Engineer,John Varghese,Rahul Patel,Anum Jalal,Victoria French,Ilya Guysenov,Christopher E. Lane,Tesfaye Mengistsu,Katherine Elizabeth Normile,Onike Mnzava,Sang Le,Ignacio Sanz,John L. Daiss,F. Eun-Hyung Lee

DOI: https://doi.org/10.4049/immunohorizons.2100011

2021-05-17

ImmunoHorizons

Abstract:SARS-CoV-2 has caused over 100,000,000 cases and almost 2,500,000 deaths globally. Comprehensive assessment of the multifaceted antiviral Ab response is critical for diagnosis, differentiation of severity, and characterization of long-term immunity, especially as COVID-19 vaccines become available. Severe disease is associated with early, massive plasmablast responses. We developed a multiplex immunoassay from serum/plasma of acutely infected and convalescent COVID-19 patients and prepandemic and postpandemic healthy adults. We measured IgA, IgG, and/or IgM against SARS-CoV-2 nucleocapsid (N), spike domain 1 (S1), S1-receptor binding domain (RBD) and S1-N-terminal domain. For diagnosis, the combined [IgA + IgG + IgM] or IgG levels measured for N, S1, and S1-RBD yielded area under the curve values ≥0.90. Virus-specific Ig levels were higher in patients with severe/critical compared with mild/moderate infections. A strong prozone effect was observed in sera from severe/critical patients-a possible source of underestimated Ab concentrations in previous studies. Mild/moderate patients displayed a slower rise and lower peak in anti-N and anti-S1 IgG levels compared with severe/critical patients, but anti-RBD IgG and neutralization responses reached similar levels at 2-4 mo after symptom onset. Measurement of the Ab responses in sera from 18 COVID-19-vaccinated patients revealed specific responses for the S1-RBD Ag and none against the N protein. This highly sensitive, SARS-CoV-2-specific, multiplex immunoassay measures the magnitude, complexity, and kinetics of the Ab response and can distinguish serum Ab responses from natural SARS-CoV-2 infections (mild or severe) and mRNA COVID-19 vaccines.